chronic myeloid leukemia
Conditions
Interventions
1:Olverembatinib
2:original TKI therapy (Nilotnib, Dasatnib)
Sponsors
The Second People's Hospital of Shenzhen
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: • Age = 18 years and =75 years. • Diagnosis of CML-CP. • Patients who have received at least two TKIs (nilotinib/ dasatinib/ flumatinib) for more than 18 months and have not reached MMR. • Willing to try to discontinue TKI in the future to achieve treatment free remission(TFR) • ECOG performance of 0-2.
Exclusion criteria
Exclusion criteria: • T315I mutation of BCR-ABL; • Known to be allergic to study drug ingredients or their analogues. • Patients with other malignant tumor under treating. • Patients with a history of severe heart disease, severe liver and kidney dysfunction, or a history of severe hemorrhagic disease. • Patients with unclear consciousness or Mental disorder cannot cooperate with diagnosis and treatment; • Pregnant or breast-feeding patients. • Researchers have evaluated patients who are deemed unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the rate of MMR at 6 months; | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients with MMR at 3, 9,12 months.;The proportion of patients with MR 4.0 at 3, 6, 9, 12 months;The proportion of patients with MR 4.5 at 3, 6, 9, 12 months; | — |
Countries
China
Contacts
Public ContactBingbing Wen
The Second People's Hospital of Shenzhen
Outcome results
None listed